ALNA News and Press, Allena Pharmaceuticals Inc. From 01/04/21

NEWTON, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, t...

Allena Pharmaceuticals (ALNA) -9.8% premarket after saying it will increase the size of its previously announced $10M bought deal offering.The company has upsized the public offering of 10.4M common shares at $1.25/share, for gross proceeds of ~$13M (from $10M).Underw...

Ovid Therapeutics (OVID) -51% after it misses goal in Angelman syndrome treatment.FuelCell Energy (FCEL) -25% after discloses below-consensus FQ4 revenues; to launch offering.Workhorse Group (WKHS) -22% after Trucks.com reports of further delays in the ...

NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, a...

Allena Pharmaceuticals (ALNA) announces bought deal offering of 8M shares at $1.25/share, compared to the stock's yesterday close of $1.35. Gross proceeds expected to be ~$10M. Underwriters have also been given overallotment option for an additional purchase of 1.2M shares.The company in...

NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, a...

NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, t...

Allena Pharmaceuticals ([[ALNA]] +2.1%) has announced data from its Phase 1 trial evaluating ALLN-346 in healthy volunteers, demonstrating ALLN-346 was well-tolerated with no clinically significant safety signals and no dose-limiting toxicities observed in any cohort up to the highe...

-- Single-Ascending Doses of ALLN-346 Oral Enzyme Well-Tolerated -- -- Non- A bsorption o f ALLN-346 Demonstrated -- -- Advancing to Phase 1b Multiple - Ascending Dose Study and Phase 2 Proof-of-Co...

NEWTON, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, t...